BioInvent&#39;s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA (pembrolizumab) in Advanced CTCL (EHA 2026)

BI-1808 - BioInvent

May 12, 2026